浙江中医药大学第二临床医学院;浙江大学医学院附属浙江医院肿瘤科;
目的 探讨Maresin-1在肝细胞癌中的作用及其对细胞毒性T细胞的影响。方法 60只5周龄BALB/c小鼠随机分为对照组、模型组、低剂量组和高剂量组。原位接种H22细胞构建小鼠肝癌模型，低剂量和高剂量组小鼠在原位接种的基础上腹腔注射25 ng/kg和100 ng/kg Maresin-1,持续2周后评估肝组织体积，测量血清谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(STB)水平。流式细胞术检测小鼠肝癌组织细胞毒性T细胞，ELISA法检测肿瘤坏死因子-α(TNF-α)、干扰素-γ(IFN-γ)和淋巴毒素α(LT-A)表达，Western blotting法检测肝癌组织PD-1和PD-L1表达。结果 与对照组比较，模型组小鼠肝组织的体积、Ki-67表达和血清ALT、AST和STB含量均显著升高(P<0.05)。与对照组比较，模型组小鼠肝癌组织细胞毒性T细胞水平、TNF-α、IFN-γ和LT-A含量均明显降低，而PD-1和PD-L1表达明显升高(P<0.05)。与模型组比较，低剂量组小鼠肝组织的体积、Ki67表达和血清ALT、AST和STB含量显著降低(P<0.05)。与模型组比较，低剂量组小鼠细胞毒性T淋巴细胞水平、TNF-α、IFN-γ和LT-A含量均显著升高，而PD-1和PD-L1表达明显降低(P<0.05)。与模型组比较，高剂量组小鼠肝组织的体积、Ki-67表达和血清ALT、AST和STB含量显著降低(P<0.05)。与模型组比较，高剂量组小鼠细胞毒性T淋巴细胞水平、TNF-α、IFN-γ和LT-A含量均显著升高，而PD-1和PD-L1表达明显降低(P<0.05)。结论 Maresin-1通过抑制PD-1/PD-L1通路介导的肿瘤免疫逃逸，促进细胞毒性T淋巴细胞对肝癌的杀伤作用。
| 33 | 0 | 31 |
| 下载次数 | 被引频次 | 阅读次数 |
[ 1 ] Ganesan P,Kulik LM.Hepatocellular carcinoma:New developments[J].Clin Liver Dis,2023,27(1):85-102.
[ 2 ] 周学超，丁怀银，王龙琦，等.肝细胞癌患者术后无复发生存的列线图预测模型[J].临床肿瘤学杂志，2024,29(5):464-469.
[ 3 ] 国家癌症中心.2021中国肿瘤登记年报[M].人民卫生出版社，2023.
[ 4 ] Ghosh C,Luong G,Sun Y.A snapshot of the PD-1/PD-L1 pathway[J].J Cancer,2021,12(9):2735-2746.
[ 5 ] Li D,Zhou X,Xu W,et al.Prostate cancer cells synergistically defend against CD8(+) T cells by secreting exosomal PD-L1[J].Cancer Med,2023,12(15):16405-16415.
[ 6 ] 何回香，刘敏，陈嘉欣，等.Maresin 1在肺部炎症性疾病中的作用研究进展[J].生理科学进展，2023,54(5):439-444.
[ 7 ] Li H,Li X,Hao Y,et al.Maresin 1 intervention reverses experimental pulmonary arterial hypertension in mice[J].Br J Pharmacol,2022,179(22):5132-5147.
[ 8 ] Tojo T,Tsuruoka M,Kondo T,et al.Evaluation of cancer cell growth suppressibility of omega-3 fatty acids and their metabolites[J].J Oleo Sci,2022,71(8):1253-1260.
[ 9 ] Xue R,Zhang Q,Cao Q,et al.Liver tumour immune microenvironment subtypes and neutrophil heterogeneity[J].Nature,2022,612(7938):141-147.
[10] Donne R,Lujambio A.The liver cancer immune microenvironment:Therapeutic implications for hepatocellular carcinoma[J].Hepatology,2023,77(5):1773-1796.
[11] Llovet JM,Castet F,Heikenwalder M,et al.Immunotherapies for hepatocellular carcinoma[J].Nat Rev Clin Oncol,2022,19(3):151-172.
[12] Yin X,Yu XW,Zhu P,et al.Endogenously synthesized n-3 fatty acids in fat-1 transgenic mice prevent melanoma progression by increasing E-cadherin expression and inhibiting beta-catenin signaling[J].Mol Med Rep,2016,14(4):3476-3484.
[13] Hong JY,Cho HJ,Sa JK,et al.Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab:results from a single-arm phase 2 trial[J].Genome Med,2022,14(1):1.
[14] 张艾，李海洋.肝癌肿瘤微环境中CD8～+细胞毒性T淋巴细胞的研究进展[J].山东医药，2022,62(10):84-88.
[15] Liu J,Ye Y,Cai L.Supramolecular attack particle:the way cytotoxic T lymphocytes kill target cells[J].Signal Transduct Target Ther,2020,5(1):210.
[16] Kondo Y,Suzuki S,Takahara T,et al.Improving function of cytotoxic T-lymphocytes by transforming growth factor-beta inhibitor in oral squamous cell carcinoma[J].Cancer Sci,2021,112(10):4037-4049.
[17] 朱麒，肖瑶，金丽艳，等.曲妥珠单抗联合化疗对HER-2阳性胃癌患者T淋巴细胞亚群及肿瘤标志物的影响[J].临床肿瘤学杂志，2023,28(2):159-163.
[18] Sukowati C,Cabral L,Anfuso B,et al.PD-L1 Downregulation and DNA methylation inhibition for molecular therapy against cancer stem cells in hepatocellular carcinoma[J].Int J Mol Sci,2023,24(17) :13357.
[19] 王俊旗，徐锋.程序性死亡受体1及其配体PD-L1、细胞毒性T淋巴细胞相关抗原4抑制剂在晚期肝癌治疗中的进展[J].中华普通外科学文献(电子版),2021,15(4):304-308.
[20] Lv T,Xiong X,Yan W,et al.Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression[J].J Immunother Cancer,2022,10(6)[2024-10-11].https://pubmed.ncbi.nlm.nih.gov /35688553/.
基本信息:
DOI：
中图分类号:R735.7
引用信息:
[1]应力超,池金正,张宇.Maresin-1调控PD-1诱导细胞毒性T细胞治疗肝癌的实验研究[J].临床肿瘤学杂志,2025,30(03):209-214.
基金信息:
浙江省医药卫生科技资助项目(2016KYA001)